Investment Analysts’ Weekly Ratings Changes for Krystal Biotech (KRYS)

Krystal Biotech (NASDAQ: KRYS) recently received a number of ratings updates from brokerages and research firms:

• 6/20/2026 – Krystal Biotech was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/18/2026 – Krystal Biotech had its price target raised by TD Cowen from $306.00 to $403.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 6/16/2026 – Krystal Biotech had its price target raised by HC Wainwright from $310.00 to $361.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
• 5/18/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
• 5/9/2026 – Krystal Biotech was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/5/2026 – Krystal Biotech had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 5/5/2026 – Krystal Biotech had its price target raised by Citigroup Inc. from $371.00 to $378.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.